Iteos Therapeutics, Inc. ( (ITOS) ) has released its Q1 earnings. Here is a breakdown of the information Iteos Therapeutics, Inc. presented to its investors.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics for cancer treatment, leveraging its expertise in tumor biology and immunosuppressive pathways. In its latest earnings report, iTeos Therapeutics reported a net loss of $34.6 million for the first quarter of 2025, compared to a net loss of $38.2 million in the same period last year. The company’s cash and cash equivalents increased to $156.5 million, supported by interest income and investment activities. Key financial highlights include a reduction in operating expenses and a comprehensive loss of $33.5 million, reflecting improvements in foreign currency translation adjustments and unrealized gains on securities. iTeos continues to advance its pipeline, including its lead product candidate belrestotug, in collaboration with GSK, with multiple ongoing clinical trials targeting solid tumors. Looking ahead, iTeos remains focused on its strategic partnerships and clinical development programs to drive future growth and achieve its commercialization objectives.